189 related articles for article (PubMed ID: 37683276)
1. FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment.
Shimoyama S; Okada K; Kimura T; Morohashi Y; Nakayama S; Kemmochi S; Makita-Suzuki K; Matulonis UA; Mori M
Mol Cancer Ther; 2023 Dec; 22(12):1454-1464. PubMed ID: 37683276
[TBL] [Abstract][Full Text] [Related]
2. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
3. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
5. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
[TBL] [Abstract][Full Text] [Related]
6. Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850).
Kimura T; Okada K; Morohashi Y; Kato Y; Mori M; Kato H; Matsumoto T; Shimoyama S
Pharm Res; 2024 Apr; 41(4):795-806. PubMed ID: 38536615
[TBL] [Abstract][Full Text] [Related]
7. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
8. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
[TBL] [Abstract][Full Text] [Related]
9. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
10. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
11. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
13. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
14. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
16. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
17. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
20. Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy.
Sabbatini P; Mooney D; Iasonos A; Thaler H; Aghajanian C; Hensley M; Konner J; Spriggs D; Abu-Rustum NR; Dupont J
Int J Gynecol Cancer; 2007; 17(3):589-94. PubMed ID: 17300679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]